Phaseline

Targets › IL36R

IL36R: drug programs, companies and trials

2 programs from 2 companies in 5 trials: 2 Phase 2, 1 Phase 4, 1 Phase 3, 1 Phase 1; Immunology, Other; next expected readout Sep 2027.

Open in Phaseline: the race on IL36R, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
LEO PharmaSpesolimab
IL36 receptor antagonist
IL36R, IL1RAPPhase 4Generalized Pustular Psoriasis; Pyoderma GangrenosumSep 2027
Shanghai Huaota BiopharmaceuticalHB0034
anti-IL-36R monoclonal antibody
IL36RPhase 2Generalized Pustular Psoriasis (GPP); Healthy–

Conditions

Generalized Pustular Psoriasis (2) Pyoderma Gangrenosum (1) Generalized Pustular Psoriasis (GPP) (1) Healthy (1)

Modalities

mixed (1), small molecule (1)

Companies

LEO Pharma (1) Shanghai Huaota Biopharmaceutical (1)

Related targets

IL1RAP (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.